Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Use of the tumor necrosis factor-blockers for Crohn's disease
Alan BR Thomson, Division of Gastroenterology, Department of Medicine, University of Western Ontario, London N6A 5A5, Canada
Milli Gupta, Department of Medicine, University of Alberta, Edmonton T6G 2X8, Canada
Hugh J Freeman, Department of Medicine, University of British Columbia, Vancouver V6T 2B5, Canada
Author contributions: Thomson ABR conceived of the need for a timely, balanced, evidence-based review, reviewed the relevant literature, provided a first draft, critiqued the clinical relevance and design of trial, revised the initial draft, and communicated with the editors; Gupta M and Freeman HJ reviewed the medical literature, critiqued the papers and meta-analyses, rewrote portions of the first draft, and approved the final document.
Correspondence to: Alan BR Thomson, Adjunct Professor, Division of Gastroenterology, Department of Medicine, University of Western Ontario, London N6A 5A5, Canada. abrthomson@gmail.com
Telephone: +1-519-6858300-35300 Fax: +1-519-6633232
Received: November 28, 2011
Revised: June 13, 2012
Accepted: August 14, 2012
Published online: September 21, 2012
Revised: June 13, 2012
Accepted: August 14, 2012
Published online: September 21, 2012
Core Tip